Peptipedia
CognitiveNot FDA ApprovedClinical Trials

GB-115

Also known as Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester

A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Effects noted by day 7.

Phase 3 Completed - Anxiety/adjustment disorders, not yet approved outside Russia
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

6 mg daily (2 mg three times daily)

Frequency

2-3 times daily

Duration

21+ days in clinical trials

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 6 mg daily (2 mg three times daily) via Oral tablets or sublingual, 2-3 times daily. Dose range: 2-6 mg per day. Duration: 21+ days in clinical trials.

Timing & Administration

Administer via Oral tablets or sublingual. Frequency: 2-3 times daily.

Mechanism of Action

Works by blocking central cholecystokinin-1 (CCK-1) receptors in the brain, reducing anxiety while enhancing attention, processing speed, and reaction time through dopaminergic pathway modulation.

Research Summary

Evidence level: clinical trials. Clinical status: Phase 3 Completed - Anxiety/adjustment disorders, not yet approved outside Russia.

Side Effects & Safety

Important Warnings

  • No reported dependency or withdrawal
  • Limited long-term safety data.
Headache (rare)
mild gastrointestinal discomfort
minimal sedation

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
SemaxCognitive

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

View profile
CerebrolysinCognitive

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

View profile